Oral Presentation Australian and New Zealand Obesity Society Annual Scientific Conference 2026

Impact of semaglutide 2.4 mg and oral semaglutide 25 mg on QoL in women with obesity: A post hoc analysis of the STEP and OASIS programs by menopausal status (144115)

Sarah Glastras 1 , Maria Daniela Hurtado Andrade 2 3 , Rebecca Dunsmoor-Su 4 5 , Emilia Huvinen 6 , Naveen Rathor 7 , Nanette Santoro 8 , Lauren Wilson 9 , Sushmita Yaganti 9 , Santiago Palacios 10
  1. Sydney Medical School, University of Sydney, Syndey, Australia
  2. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA
  3. Precision Medicine for Obesity Program, Mayo Clinic, Rochester, MN, USA
  4. Gennev, Seattle, WA, USA
  5. Seattle Clinical Research Center, Seattle, WA, USA
  6. University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  7. Novo Nordisk A/S, Søborg, Denmark
  8. University of Colorado School of Medicine, Aurora, CO, USA
  9. Novo Nordisk Inc., Plainsboro, NJ, USA
  10. Palacios Clinic for Women's Health, Madrid, Spain

Introduction

This post hoc analysis investigated quality of life (QoL) by menopausal status in the STEP and OASIS 4 trials.

Methods

Female participants (pts) with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complications who received once-weekly subcutaneous semaglutide 2.4 mg for 68 weeks (wk) in STEP 1, 3, 4, and 9, or once-daily oral semaglutide 25 mg for 64 wk in OASIS 4, were stratified by menopausal status. Changes from baseline (BL) were assessed for Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT; STEP 1, OASIS 4), Short Form-36v2 Health Survey acute version (SF-36v2; STEP 1, 3, 4), International Consultation of Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF; STEP 1), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; STEP 9). Safety was also assessed.

Results

Analysis included pre-menopause (n=785), peri-menopause (n=373), post-menopause, (n=768) from the STEP trials and n=68; n=33; and n=50, respectively, from OASIS 4. In STEP 1, mean IWQOL-Lite-CT Physical Function composite scores improved across all groups (pre- +15.6 [BL 68.1], peri- +15.9 [63.5], post- +15.8 [61.5]); OASIS 4 (pre- +16.0 [BL 58.2], peri- +21.8 [54.2], post- +17.6 [55.7]). In STEP 1, 3, and 4, SF-36v2 Physical Component Summary scores improved (pre- +3.0 [BL 52.3]; peri- +2.5 [51.6]; post- +2.6 [50.4]). In STEP 1, the proportion of pts reporting ≤1 urinary incontinence episode/wk at wk 68 was lowest in the post-menopause group (35.6% vs pre- 41.5%, peri- 40.9%). In STEP 9, more pts in the post-menopause group achieved ≤−37.3 from BL in WOMAC pain score (69.5%) (pre- 50.0%; peri- 53.6%). The safety of semaglutide was consistent across groups; most adverse events were gastrointestinal.

Conclusion

Semaglutide was associated with clinically meaningful improvements in weight-related QoL, regardless of menopausal status, in women with overweight/obesity in the STEP and OASIS 4 trials.